Nortriptyline
| Evidence Level: L3 | Predicted Indications: 2 |
Table of Contents
Nortriptyline: From Depression to Attention-Deficit/Hyperactivity Disorder (ADHD)
One-Sentence Summary
Nortriptyline is a tricyclic antidepressant (TCA) originally used to treat major depressive disorder. The TxGNN model predicts it may be effective for Attention-Deficit/Hyperactivity Disorder (ADHD), with 0 registered clinical trials but 20 supporting publications, including a Cochrane systematic review and several controlled studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major depressive disorder (TCA class); no Taiwan-approved indication text on file — drug is not marketed |
| Predicted New Indication | Attention-Deficit/Hyperactivity Disorder (ADHD) |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L3 |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, nortriptyline is a secondary-amine tricyclic antidepressant that primarily inhibits norepinephrine reuptake (with weaker serotonergic activity); its efficacy in major depressive disorder is well established.
ADHD and depression are both neuropsychiatric conditions where noradrenergic and dopaminergic signaling play a central role in symptom control. Several publications in this evidence set (e.g., PMID 15064003, PMID 24345533) specifically note that nortriptyline’s noradrenergic selectivity underlies its historical use as a second-line, non-stimulant ADHD treatment — particularly in patients who cannot tolerate stimulants or who have comorbid tic disorders/Tourette’s syndrome.
Mechanistically, this makes the TxGNN prediction plausible: nortriptyline’s noradrenergic reuptake inhibition is a recognized pathway for ADHD symptom control (shared by other non-stimulant agents such as atomoxetine), and clinical use of TCAs for ADHD already has decades of documented, if limited, precedent.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25238582 | 2014 | Systematic Review (Cochrane) | Cochrane Database of Systematic Reviews | Reviewed TCAs, including nortriptyline, as second-line ADHD treatment in children/adolescents |
| 11052409 | 2000 | Controlled Study | Journal of Child and Adolescent Psychopharmacology | Assessed efficacy and tolerability of nortriptyline in pediatric ADHD |
| 22700161 | 2012 | RCT | Pediatric Nephrology | Randomized double-blind trial of nortriptyline for enuresis in children with ADHD |
| 7807071 | 1995 | Systematic Assessment | Journal of Nervous and Mental Disease | Systematic assessment of TCAs, including nortriptyline, in adult ADHD |
| 15064003 | 2004 | Review | Psychiatric Clinics of North America | Notes nortriptyline as an established but narrow-therapeutic-index nonstimulant ADHD option |
| 8428873 | 1993 | Case Series | Journal of the American Academy of Child and Adolescent Psychiatry | Nortriptyline used in children with ADHD and comorbid tic disorder/Tourette’s syndrome |
| 12270803 | 2002 | Review | Adolescent Medicine | Lists nortriptyline among TCAs with documented anti-ADHD activity in adolescents |
| 15794722 | 2005 | Review | Expert Opinion on Drug Safety | Reviews safety of nonstimulant ADHD agents, including TCAs such as nortriptyline |
| 8444754 | 1993 | Retrospective Study | Journal of the American Academy of Child and Adolescent Psychiatry | Retrospective review of serum levels and ECG effects of nortriptyline in children/adolescents |
| 4075308 | 1985 | Case Report | Clinical Neuropharmacology | Early report of nortriptyline use in attention deficit disorder |
Safety Considerations
- Drug Interactions: DDI database records 295 total interactions for nortriptyline. Among the sampled interactions, several are flagged Major: Epinephrine, Bupropion, Lorcaserin, Potassium citrate, and Dolasetron. Moderate-level interactions include Famotidine, Cimetidine, Clarithromycin, and several anticholinergic agents (Atropine, Hyoscyamine, Glycopyrronium, Dicyclomine).
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials are registered specifically for nortriptyline in ADHD, and the local Taiwan safety label/warning data (DG001) is a Blocking gap that prevents entry into initial safety (S1) assessment. While literature support (Cochrane review + several controlled studies) is encouraging, it is not sufficient to proceed without local safety documentation.
To proceed, the following is needed:
- TFDA package insert warnings/contraindications (DG001, Blocking)
- Confirmed mechanism of action documentation (DG002, High)
- A defined regulatory pathway, since nortriptyline is currently not marketed in Taiwan (0 licenses)
- Classification of the literature evidence base (study type/tier currently marked “pending”) to formally confirm the L3 evidence level
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.